Our Partners

SVAX and Fakeeh Care Group have formed a mutually beneficial partnership built on both financial investment and strategic collaboration.  Fakeeh Care Group has made a strategic investment in SVAX, recognizing the company's potential to drive innovation in biopharmaceutical development and manufacturing. In turn, SVAX will leverage Fakeeh's extensive network and expertise as a leading regional healthcare provider to advance its research and development efforts and expand access to its groundbreaking therapies. This partnership creates a powerful synergy, combining SVax's cutting-edge biopharma capabilities with Fakeeh's commitment to delivering world-class healthcare services, ultimately improving patient outcomes and advancing the healthcare landscape in the region. 

SVAX and Henlius  have forged a strategic partnership to advance the development, registration, and commercialization of innovative biopharmaceutical products in the MENAT region. This collaboration includes the establishment of joint ventures focused on both commercialization and manufacturing within Saudi Arabia. By leveraging Henlius's expertise in developing high-quality, affordable biologic medicines and SVAX's commitment to localizing biomanufacturing, this partnership aims to expand access to critical therapies and contribute to the growth of the regional healthcare sector. Both companies benefit mutually: Henlius gains a strong foothold in a key emerging market, while SVax strengthens its manufacturing capabilities and expands its product portfolio with the addition of Henlius's innovative therapies. 

SVAX and Boehringer Ingelheim Animal Health join forces on triad to protect livestock in Saudi Arabia. This  strategic partnership aimed at enhancing livestock protection and promoting animal health in Saudi Arabia. This collaboration revolves around three key pillars: local vaccine manufacturing, scientific collaboration, and pandemic preparedness.

SVAX and Sartorius collaboration allows SVAX to leverage Sartorius's wide range of technologies and subject matter experts to share their knowledge and support in delivering the first Industrial Biomanufacturing Training program in the Middle East region, in partnership with King Abdulaziz University. The collaboration objectives are to deliver on Saudi’s ambition for biomanufacturing autonomy by building a sustainable biopharmaceuticals development and manufacturing ecosystem in KSA in alignment with the Saudi Vision 2030 objectives

SVAX have signed an exclusive agreement with Bertis Inc to localize proteomics-based testing in Oncology starting with breast cancer. Utilizing the MASTOCHECK platform technology for early detection of cancer. This innovative technology will be available in Saudi Arabia and the GCC.

SVAX and PanGen Biotech have entered an Exclusive Distribution Agreement, granting SVAX exclusive rights to register, market, and distribute PanGen's biopharmaceutical products in Saudi Arabia and MENA countries. Under the agreement, PanGen will provide regulatory support and supply its Korean FDA-approved products, while SVAX manages local regulatory approvals, marketing strategies, and sales forecasts. The collaboration also includes plans to transfer the manufacturing of these products to SVAX's facility in Saudi Arabia, ensuring exclusive technology transfer and strengthening local biomanufacturing capabilities in line with Vision 2030.

SVAX has partnered with Optima Pharma to introduce advanced filling technologies into Saudi Arabia’s biopharmaceutical industry. This collaboration supports SVAX’s mission to localize biomanufacturing and drive healthcare innovation in the region. By combining expertise, SVAX and Optima aim to set new standards in biomanufacturing excellence, enhancing the accessibility and safety of critical biologics and vaccines, in line with Saudi Arabia’s Vision 2030.

SVAX has partnered with King Abdulaziz University to create a specialized training program focused on the development and localization of vaccines and biopharmaceuticals in Saudi Arabia. This initiative aims to build a highly skilled workforce, promote the growth of the pharmaceutical sector, and align with Saudi Arabia’s Vision 2030. The program will offer training through lectures, workshops, and hands-on experience, empowering Saudi youth with the expertise needed to contribute to the country’s healthcare and biomanufacturing industries. This collaboration underscores SaudiVax’s commitment to advancing local vaccine production and strengthening the Kingdom’s healthcare capabilities.

Saudi Aramco and SVAX have signed a Memorandum of Understanding  to localize vaccine and biologics manufacturing in Saudi Arabia, in line with Saudi Vision 2030. Saudi Aramco will support the initiative, while SaudiVax focuses on developing and manufacturing vaccines and biologics locally. The collaboration aims to raise national awareness, attract investments, and support applications for funding to build manufacturing facilities. Additionally, the partnership will work to enhance vaccination programs and aid low-income countries, positioning Saudi Arabia as a regional hub for vaccine and biologics production